



July 2, 2021

T Capital Partners Co., Ltd.

Announcement of the Investment in MicroBiopharm Japan Co., Ltd.

T Capital Partners Co., Ltd. ("TCAP") would like to announce that its fund series managed by TCAP, made an investment in MicroBiopharm Japan Co., Ltd. ("MBJ").

MBJ is a Contract Development Manufacturing Organization ("CDMO") with strengths in microbial fermentation technology, engaged in the contract manufacturing and development of active pharmaceutical ingredients ("APIs") and the manufacture and sale of its own APIs. TCAP will work with the management team to further enhance the corporate value of MBJ by providing management know-how, human resources support, and support for planning and execution of M&A and so on.

< Overview of MBJ >

Company name : MicroBiopharm Japan Co., Ltd.
Address : 1-3-1 Kyobashi, Chuo-ku, Tokyo, Japan
Representative : Akito Umeda, President & CEO
Business : Research and development, production and sales of pharmaceuticals

Please contact the following for any additional information:

T Capital Partners Co., Ltd.

Phone: +81-3-5223-3516

- Yoshihiro Osako, Director
- Shusuke Mitsunami, Vice President
- Hiroto Noda, Senior Associate